AVTR vs CRL
AVTR: Global provider of mission-critical laboratory consumables, specialty chemicals, and biopharmaceutical manufacturing solutions serving life sciences, healthcare, and advanced technology markets worldwide. CRL: A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety assessment, and biologics testing.
Side-by-side fundamentals
| Metric | AVTR | CRL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.95 | $218.70 | |
| Market cap as of 2026-07-23 | $7.5B | $10.6B | |
| PEG as of 2026-07-23 | n/a | -0.12 | |
| Net margin as of 2026-07-23 | -8.4% | -4.6% | CRL higher |
| Gross margin as of 2026-07-23 | +32.1% | +34.5% | CRL higher |
| Operating margin as of 2026-07-23 | -4.6% | +1.8% | CRL higher |
| ROE as of 2026-07-23 | -9.6% | -5.7% | CRL higher |
| ROA as of 2026-07-23 | -4.6% | -2.5% | CRL higher |
| Debt / equity as of 2026-07-23 | 0.68 | 0.91 | AVTR lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.0% | +0.1% | CRL higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | +0.3% | CRL higher |
| Beta as of 2026-07-23 | 0.92 | 1.38 | |
| 1-year return as of 2026-07-22 close | -10.9% | +33.9% | CRL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.